University of Patras
Μελέτη και αξιολόγηση βιοχημικών δεικτών και βιοδραστικών μακρομορίων στη μεταστατική οστική νόσο
Abstract
dc:descriptionThe normal process of bone metabolism, known as bone remodeling, includes the coupling of bone resorption (destruction or lysis) and bone formation. The breakdown of this balance and the rate of bone turnover define bone disease. Bone disease in cancer is a disease that existed before but now it redefines according to the newest research and the scientific information. It is a chronic disease with secondary development either from the cancer cell itself (metastatic or non-metastatic) or with cancer therapies. The cancer cell plays a crucial role in case of bone affected either from metastatic tumor, termed as advanced osteolytic, osteoblastic or mixed type of bone disease or from non-metastatic tumor such as multiple myeloma (hematological cause). Hormonal therapies and chemotherapy, leading to osteopathy or osteoporosis are the main causes of benign bone disease, which is termed as benign osteoporotic bone disease in cancer. The aim of this thesis was to determine the levels of BAP and NTx in serum of breast cancer patients with bone metastasis and in healthy individuals in order to evaluate whether these specific biochemical markers may be at importance in the detection of breast cancer bone metastasis and, furthermore, to determine the diagnostic validity of these biomarkers in predicting skeletal metastases. Additionally, another important objective was to measure the serum levels of HA, OPN, SA and OPG under ZA administration and correlate them with the levels of bone markers. In conclusion, serum NTx appears to be a useful marker in assessing bone metastatic status in patients with solid tumors and could be applied as an adjunct method for the monitoring of these patients. It provides information for the type and extent of tumor burden in bone, can evaluate the response to antiresorptive treatment, can detect bone disease progression and even predict bone disease outcome. In view of these findings, prospective studies to investigate whether NTx in patients with a malignancy prone to bone metastases could detect early micrometastatic bone lesions, before they become apparent by imaging techniques seems warranted. Additionally, HA and OPN seem to respond to zoledronic acid administration, following the decrease of NTx levels and, appear to correlate to the rate of bone resorption. Further clinical evaluation of the diagnostic accuracy of these macromolecules would be useful for assessing as markers in bone disease.
Degree
thesis:*- Grantor dc:publisher
- University of Patras
- Year dc:date
- 2007
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Kanakis, Ioannis
- Κανάκης, Ιωάννης
Subjects
dc:subject × 20- Μεταβολισμός οστών
- Οστική νόσος στον καρκίνο
- Βιοχημικοί δείκτες
- Βιοδραστικά μακρομόρια
- Υαλουρονικό οξύ
- Οστεοπονδίνη
- Διφωσφονικά
- Ζολενδρονικό οξύ
- Bone metabolism
- Bone disease
- Biochemical markers
- Bioactive macromolecules
- Hyaluronic acid
- Osteopondin
- Bisphosphonates
- Zoledronic acid
- Φυσικές Επιστήμες
- Χημεία
- Natural Sciences
- Chemical Sciences
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/17806